Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Pitts

Showing results (241-250 of 268) with videos related to

Pageof 27
Sort By:
Frontiers in Pharmacology|July 3, 2015
Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer modelsS Lindsey Davis, Kelli M Robertson, Todd M Pitts, et al.
Journal for Immunotherapy of Cancer|February 10, 2019
Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenograftsA Capasso, J Lang, T M Pitts, et al.
Frontiers in Pharmacology|April 2, 2013
Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer modelsTodd M Pitts, Gillian N Kulikowski, Aik-Choon Tan, et al.
Acta Neuropathologica Communications|September 8, 2022
Regulating microglial miR-155 transcriptional phenotype alleviates Alzheimer's-induced retinal vasculopathy by limiting Clec7a/Galectin-3<sup>+</sup> neurodegenerative microgliaHaoshen Shi, Zhuoran Yin, Yosef Koronyo, et al.
Molecular Cancer Therapeutics|July 21, 2018
Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling MechanismsAaron J Scott, John J Arcaroli, Stacey M Bagby, et al.
Breast Cancer Research : BCR|August 4, 2018
A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancerJennifer R Diamond, S G Eckhardt, Todd M Pitts, et al.
Frontiers in Oncology|April 16, 2026
Efficacy of an XPO1 inhibitor in combination with irinotecan in a preclinical colorectal cancer modelRobert W Lentz, Adrian T A Dominguez, Nicole Baranda Balmaceda, et al.
Biorxiv : the Preprint Server for Biology|September 5, 2025
Decitabine reverses innate immune gene suppression in rare melanomasMorgan L MacBeth, Stacey M Bagby, Jessica S W Borgers, et al.
International Journal of Cancer|September 23, 2014
Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant modelEun-Kee Song, W M Tai, Wells A Messersmith, et al.
Oncotarget|July 8, 2016
Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancerTodd M Pitts, Erica L Bradshaw-Pierce, Stacey M Bagby, et al.
Pageof 27

Showing results (241-250 of 268) with videos related to

Sort By:
Pageof 27
Frontiers in Pharmacology|July 3, 2015
Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer modelsS Lindsey Davis, Kelli M Robertson, Todd M Pitts, et al.
Journal for Immunotherapy of Cancer|February 10, 2019
Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenograftsA Capasso, J Lang, T M Pitts, et al.
Frontiers in Pharmacology|April 2, 2013
Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer modelsTodd M Pitts, Gillian N Kulikowski, Aik-Choon Tan, et al.
Acta Neuropathologica Communications|September 8, 2022
Regulating microglial miR-155 transcriptional phenotype alleviates Alzheimer's-induced retinal vasculopathy by limiting Clec7a/Galectin-3<sup>+</sup> neurodegenerative microgliaHaoshen Shi, Zhuoran Yin, Yosef Koronyo, et al.
Molecular Cancer Therapeutics|July 21, 2018
Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling MechanismsAaron J Scott, John J Arcaroli, Stacey M Bagby, et al.
Breast Cancer Research : BCR|August 4, 2018
A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancerJennifer R Diamond, S G Eckhardt, Todd M Pitts, et al.
Frontiers in Oncology|April 16, 2026
Efficacy of an XPO1 inhibitor in combination with irinotecan in a preclinical colorectal cancer modelRobert W Lentz, Adrian T A Dominguez, Nicole Baranda Balmaceda, et al.
Biorxiv : the Preprint Server for Biology|September 5, 2025
Decitabine reverses innate immune gene suppression in rare melanomasMorgan L MacBeth, Stacey M Bagby, Jessica S W Borgers, et al.
International Journal of Cancer|September 23, 2014
Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant modelEun-Kee Song, W M Tai, Wells A Messersmith, et al.
Oncotarget|July 8, 2016
Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancerTodd M Pitts, Erica L Bradshaw-Pierce, Stacey M Bagby, et al.
Pageof 27